VSV-GP128 / Boehringer Ingelheim - LARVOL DELTA

KISIMA-01: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - P1 | N=96 | Active, not recruiting | Sponsor: Amal Therapeutics | Trial completion date: Dec 2024 ➔ Aug 2025 | Trial primary completion date: Jul 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Hepatology • Oncology • Solid Tumor

KISIMA-01: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - P1 | N=96 | Active, not recruiting | Sponsor: Amal Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor

KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer (AACR 2022) - P1b | "VSV-GP128 is a recombinant vesicular stomatitis virus (VSV) carrying the glycoprotein (GP) of a non-neurotropic strain of lymphocytic choriomeningitis virus (LCMV) instead of the native VSV-GP. Clearance of ctDNA is analyzed as an exploratory endpoint. The heterologous prime-boost cohorts (ATP128/VSV-GP128) of the KISIMA-01 trial are recruiting in the US, Switzerland and Belgium."

Clinical • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BIRC5 • CEACAM5

KISIMA-01: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - P1b | N=96 | Recruiting | Sponsor: Amal Therapeutics | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jul 2023 ➔ Jul 2024

Trial completion date • Trial primary completion date • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Solid Tumor